/
Since the acquisition of Global Stem Cell Group (GSCG) in August of 2021, our focus has been mainly dedicated to its operations serving the markets in the regenerative medicine industry. We believe stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management.
$0.09
+$0.02 (+26.42%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-17.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 24.2%, still solid. Margins contracted 19.0pp, which offsets some of the top-line progress.
Free cash flow declined 306% versus the prior year, cash generation momentum has weakened. ROIC dropped from 0.39% to -3.86%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$6M
▲ +24.2% YoY
Net Income (TTM)
-$8M
▼ -40.4% YoY
Op. Margin
-12.11%
▼ -19.0pp YoY
ROIC
-2.04%
▼ -4.2pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$1M
▼ -306.1% YoY
Op. Cash Flow (TTM)
-$662K
▼ -183.1% YoY
Net Debt
$39M
Cash & Equiv.
$1M
5Y CAGR: +147.4%
Continue Research
Regenerative Medical Technologies (RMTG)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Regenerative Medical Technologies scores 30/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Regenerative Medical Technologies scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -12.1% operating margin and a -2.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh RMTG's valuation and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.